



RECEIVED

MAR 06 2003

TECH CENTER 1600/2900

16

C L A I M S

1. Use of the Anapsos, a natural extract isolated from the rhizomes of *Polypodium*, comprising a water-soluble fraction, a lipid soluble fraction and a pharmaceuti-
5 cally acceptable carrier for the manufacture of a pharmaceutical medicament for regulation of the expression of adhesion molecules.
- 10 2. The use of claim 1, wherein the regulation of the expression of adhesion molecules is characterized by a reduction of the expression of the alpha chains of the integrin β -2 and/or the beta chain of the integrin β -2.
- 15 3. The use of claim 1, wherein the regulation of the expression of adhesion molecules is characterized by a reduction of the expression of the CD54.
- 20 4. The use of claim 1, wherein the regulation of the expression of adhesion molecules is characterized by a decrease in the amount of the differentiation antigens CD11b and/or CD6L.
- 25 5. The use of claim 1, wherein the medicament is used as an anti-inflammatory and/or immuno-modulatory agent and the medicament is characterized by its capacity for regulation of the expression of adhesion molecules.
- 30 6. Use of the Anapsos, a natural extract isolated from the rhizomes of *Polypodium*, comprising a water-soluble fraction, a lipid soluble fraction and a pharmaceuti- cally acceptable carrier for the manufacture of a pharmaceutical medicament for normalizing the lympho-

cyte CD4+CD29+CD45RA+ populations in pathologies where
said populations are increased.

7. The use of claim 6, for the treatment of multiple
5 sclerosis.

10

C:\0-13\Word\Memoires\Familias\Familia 227 CENTPUM\sw-ent:P990019200.doc

15